Chapter 13 **Alpha-Synucleinopathies:** Parkinson's Disease, Dementia With Lewy Bodies, and Multiple System Atrophy

Carlos Henrique Ferreira Camargo Hospital Universitário dos Campos Gerais – UEPG, Brazil

> Marcus Vinicius Della-Coletta State University of Amazonas, Brazil

Delson José da Silva Federal University of Goias, Brazil

Hélio A. G. Teive Federal University of Paraná, Brazil

ABSTRACT

Alpha-synuclein is a protein that forms a major component of abnormal neuronal aggregates known as Lewy bodies. A particular group of neurodegenerative disorders (NDs) is characterized by the abnormal accumulation of α -synuclein; termed the α -synucleinopathies, this group includes Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Lysosomal storage diseases have also been linked to α -synuclein toxicity. Several therapeutic targets have been chosen among steps of metabolism of α -synuclein. Reducing α -synuclein synthesis or expression and increasing the clearance can be achieved in many ways. The development of immunotherapeutic approaches targeting α -synuclein has received considerable attention in recent years. The aim of this chapter is to present the α -synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α -synuclein pathways.

DOI: 10.4018/978-1-5225-5282-6.ch013

INTRODUCTION

A common feature among a number of neurological disorders is the abnormal aggregation of a protein as observed with amyloid beta in Alzheimer's disease (Selkoe et al., 1990) and huntingtin protein in Huntington's disease (Vonsattel et al., 2011). In 1912, Frederick Lewy first described the cytoplasmic inclusions now known as Lewy bodies in the substantia nigra in PD Cortical Lewy bodies were first reported in association with dementia in 1961 (Okazaki et al., 1961) but they were felt to be a relatively rare finding until the 1980s, when first ubiquitin and later α -synuclein immunostains made it easier to see them (Spillantini et al., 1997) and demonstrated that Lewy bodies were a common neuropathologic finding in dementia (Gomperts, 2016). α -Synucleinopathies is a particular group of NDs characterized by the abnormal accumulation of α -synuclein (Gomperts, 2016; Kahle, 2008) (Figure 1). Lysosomal storage diseases have also been linked to α -synuclein toxicity (Wong and Krainc, 2017). There are new treatments being researched based on the pathophysiology of alpha-synuclein, and immunology. The aim of this chapter is to present the α -synucleinopathies, as well as to present the most recent researches about treatment of synucleinopathies based on knowledge of the pathophysiology of α -synuclein pathways.

BACKGROUND

Despite the early knowledge of the involvement of α -synuclein in several neurodegenerative disorders, only recently has there been, as a Holy Grail, a search for the cause and cure of these diseases through α -synuclein cellular and extracellular mechanisms and pathways. A heated discussion on this topic was



Figure 1. Main common features among α -synucleinopathies

22 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:

www.igi-global.com/chapter/alpha-synucleinopathies/209101

Related Content

Amyotrophic Lateral Sclerosis: A Predominant Form of Degenerative Disease of the Motor Neuron System

Newman Osafo, David Darko Obiri, Oduro Kofi Yeboahand Prince Amankwah Baffour Minkah (2019). Handbook of Research on Critical Examinations of Neurodegenerative Disorders (pp. 322-346). www.irma-international.org/chapter/amyotrophic-lateral-sclerosis/209103

Latest Advancements in Wearable Devices: A Review

Mohit Angurala (2022). Futuristic Design and Intelligent Computational Techniques in Neuroscience and Neuroengineering (pp. 58-64).

www.irma-international.org/chapter/latest-advancements-in-wearable-devices/294591

Non-Motor Symptoms in Parkinson's Disease: The Other Side of the Disease

Bilal El-Mansoury, Abdelali Ben Maloui, Ahmed Draoui, Youssef Ait Hamdan, Mjid Oukhrib, Kamal Smimih, Abdessamad Elmourid, Abdelaati El Khiat, Samira Boulbaroud, Iman Meftah, Miloud Hammoud, Redouane Chatoui, Said Sabir, Halima Gamraniand Arumugam Radhakrishnan Jayakumar (2023). *Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease (pp. 25-45).*

www.irma-international.org/chapter/non-motor-symptoms-in-parkinsons-disease/327963

Potential Role of Probiotics and Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease

Bilal El-Mansoury, Kamal Smimih, Abdelaati El Khiat, Hanane El Fatimi, Abdelmohcine Aimrane, Soraia El Baz, Abdessamad Elmourid, Fatima Ez-Zahraa Saad, Hafida El Ghachi, Manal Khanouchi, Arumugam Radhakrishnan Jayakumarand Abdeljalil Zoubadi (2023). *Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease (pp. 296-317).*

www.irma-international.org/chapter/potential-role-of-probiotics-and-fecal-microbiota-transplantation-in-the-treatment-ofparkinsons-disease/327981

Early Detection of Electroencephalogram Temporal Events in Alzheimer's Disease

Pedro Miguel Rodrigues, Diamantino Freitas, João Paulo Teixeira, Dílio Alvesand Carolina Garrett (2021). *Research Anthology on Diagnosing and Treating Neurocognitive Disorders (pp. 245-266).* www.irma-international.org/chapter/early-detection-of-electroencephalogram-temporal-events-in-alzheimersdisease/261637